Centre for Drug Candidate Optimisation

The Centre for Drug Candidate Optimisation (CDCO) at Monash University provides precise bioanalysis services for small molecule drug candidates, ensuring accurate quantification of compounds and metabolites in biological samples. Our flexible bioanalytical methods are tailored to support ADME lead optimisation, with rapid development and validation for discovery-stage projects. Using advanced techniques such as UPLC with UV fluorescence or MS/MS detection, including acoustic ejection MS/MS for swift analysis, we quantify test compounds in various biological matrices, including plasma, blood, urine, bile, and tissues, as well as dried blood from microsampling devices. We also identify putative metabolites to aid in comprehensive drug candidate profiling.

The Centre for Drug Candidate Optimisation (CDCO) at Monash University offers specialised in vitro ADME (Absorption, Distribution, Metabolism, and Excretion) testing to identify and mitigate compound liabilities that may hinder drug efficacy. Through a series of advanced in vitro testing protocols, CDCO evaluates key factors such as metabolic stability, membrane permeability, and protein binding to optimise drug candidates for better bioavailability and therapeutic effectiveness. Our comprehensive testing includes liver microsomes and hepatocyte metabolism studies, Caco-2 permeability studies, protein binding, and cytochrome P450 inhibition among other critical assays.

The Centre for Drug Candidate Optimisation (CDCO) at Monash University provides comprehensive in vivo pharmacokinetic (PK) studies to assess key drug properties, including clearance, volume of distribution, half-life, and bioavailability. Early in vivo PK data is crucial for validating in vitro screening results and establishing reliable in vitro/in vivo correlations. CDCO’s rodent studies include various dosing routes (IV, IP, PO, SC, IM) and a range of exposure assessments, such as renal and biliary excretion, brain uptake, and repeated dosing for up to 7 days. We also offer mini-pump delivery systems for extended studies, formulation development, and the evaluation of in vivo metabolite formation and concomitant therapies.

The Centre for Drug Candidate Optimisation (CDCO) at Monash University offers comprehensive physicochemical profiling services that are essential for optimising drug candidates. Understanding the physicochemical properties of drug candidates—such as pKa, Log D, and solubility—can help reduce bioavailability issues and improve drug delivery and distribution. CDCO provides in-depth analysis, including in silico calculations, kinetic and equilibrium solubility tests, and biorelevant solubility studies in simulated biological fluids. Additional services include pKa determination, chromatographic and shake-flask LogD analysis, and impurity profiling to ensure the development of stable, effective drug formulations.

The Centre for Drug Candidate Optimisation (CDCO) at Monash University offers comprehensive physicochemical profiling services that are essential for optimising drug candidates. Understanding the physicochemical properties of drug candidates—such as pKa, Log D, and solubility—can help reduce bioavailability issues and improve drug delivery and distribution. CDCO provides in-depth analysis, including in silico calculations, kinetic and equilibrium solubility tests, and biorelevant solubility studies in simulated biological fluids. Additional services include pKa determination, chromatographic and shake-flask LogD analysis, and impurity profiling to ensure the development of stable, effective drug formulations.

The Centre for Drug Candidate Optimisation (CDCO) at Monash University offers specialised in vitro ADME (Absorption, Distribution, Metabolism, and Excretion) testing to identify and mitigate compound liabilities that may hinder drug efficacy. Through a series of advanced in vitro testing protocols, CDCO evaluates key factors such as metabolic stability, membrane permeability, and protein binding to optimise drug candidates for better bioavailability and therapeutic effectiveness. Our comprehensive testing includes liver microsomes and hepatocyte metabolism studies, Caco-2 permeability studies, protein binding, and cytochrome P450 inhibition among other critical assays.

The Centre for Drug Candidate Optimisation (CDCO) at Monash University provides precise bioanalysis services for small molecule drug candidates, ensuring accurate quantification of compounds and metabolites in biological samples. Our flexible bioanalytical methods are tailored to support ADME lead optimisation, with rapid development and validation for discovery-stage projects. Using advanced techniques such as UPLC with UV fluorescence or MS/MS detection, including acoustic ejection MS/MS for swift analysis, we quantify test compounds in various biological matrices, including plasma, blood, urine, bile, and tissues, as well as dried blood from microsampling devices. We also identify putative metabolites to aid in comprehensive drug candidate profiling.

The Centre for Drug Candidate Optimisation (CDCO) at Monash University provides comprehensive in vivo pharmacokinetic (PK) studies to assess key drug properties, including clearance, volume of distribution, half-life, and bioavailability. Early in vivo PK data is crucial for validating in vitro screening results and establishing reliable in vitro/in vivo correlations. CDCO’s rodent studies include various dosing routes (IV, IP, PO, SC, IM) and a range of exposure assessments, such as renal and biliary excretion, brain uptake, and repeated dosing for up to 7 days. We also offer mini-pump delivery systems for extended studies, formulation development, and the evaluation of in vivo metabolite formation and concomitant therapies.